查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球脊髓性肌萎縮症治療市場規模、份額和行業趨勢分析報告：按類型、給藥途徑、治療類型、藥物類型、地區展望和預測，2022-2028 年
市場調查報告書
商品編碼
1172695

全球脊髓性肌萎縮症治療市場規模、份額和行業趨勢分析報告：按類型、給藥途徑、治療類型、藥物類型、地區展望和預測，2022-2028 年

Global Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type, By Route of Administration, By Treatment Type, By Drug Type, By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 252 Pages | 訂單完成後即時交付

價格

到 2028 年，脊髓性肌萎縮症治療的全球市場規模預計將達到 114 億美元，預測期內復合年增長率為 17.8%。

當脊髓受損時，脊髓性肌萎縮症可以遺傳，遺傳了該基因的孩子長大成人。 脊髓性肌萎縮症的症狀因類型而異。 兒童 1 型 SMA 最嚴重的症狀通常出現在生命的前 6 個月，並且更為嚴重。

在輕型中，症狀較輕，直到孩子 18 個月或更大時才會出現症狀。 脊柱側彎、呼吸問題、吞嚥和進食問題、粗大運動技能延遲、肌張力低和無力、運動能力受限以及舌頭運動延遲是 SMA 的可能跡象。

COVID-19 影響分析

由於嚴格的隔離程序和對人體活動的限制，COVID-19 爆發對脊髓性肌萎縮症治療市場產生了負面影響。 SMA 研發活動和劑量研究的資金正在減少，因為大部分資金都用於生產 COVID-19 疫苗。 脊髓性肌萎縮症 (SMA) 患者獲得治療的機會受到大流行的不利影響。 例如，致力於根除 SMA 的志願非營利組織 Cure SMA 發起了一項民意調查，以評估疫情對 SMA 社區的影響。

市場增長因素

擴大治療脊髓性肌萎縮症的研發活動

脊髓性肌萎縮症的患病率和知識正在顯著增加，推動了對改善患者預後的有效治療方案的需求。 在基因治療領域，最近公佈了兩個重要產品。 長期以來，罕見病脊髓性肌萎縮症無法治愈，並經常奪去新生兒和幼兒的生命。

增加患者的報銷機會

脊髓性肌萎縮症 (SMA) 的主要趨勢之一是在全球多個國家擴大昂貴藥物的報銷機會。 預計這將對昂貴的基因療法的採用產生積極影響。 法國、德國、奧地利和意大利等國家已向所有患者提供有償服務，以色列和香港也在這樣做。

市場製約因素

批准產品的成本極高

罕見遺傳病的治療費用高昂，是製約擴大治療設施的主要因素之一。 例如，預計 SPINRAZA 第一年的費用為 708,000 美元，此後每年的費用為 354,000 美元，10 年的總治療費用為 390 萬美元。 相比之下，Novartis 對 Zolgensma 的治療費用預計為每次治療 210 萬美元。 相比之下，risdiplum 每年的成本高達 340,000 美元。 毫無疑問，這些費用不僅對患者及其家人，而且對醫療保健專業人員都構成嚴峻挑戰。

輸入 Outlook

脊髓性肌萎縮症治療市場按類型分為 1、2、3 和 4 類。 2021 年，1 型細分市場將在脊髓性肌萎縮症治療市場中佔據最高的收入份額。 這種增長的一個因素是它的高流行率。 大約一半患有 SMA 的新生兒患有這種類型的 SMA，因此它更為普遍。 Zolgensma (onasemnogene abeparvovec-xioi) 是第一個和許多其他藥物已獲得 FDA 批准用於治療 1 型患者。

治療類型的前景

按治療類型，脊髓性肌萎縮症治療市場分為基因治療和藥物治療。 2021 年，藥物部分在脊髓性肌萎縮症治療市場中佔據了最大的收入份額。 由於藥物研發成本低以及與其他療法相比易於獲取，這一細分市場正在增長。 目前市場上主要有 3 種 FDA 批准的治療 SMA 的藥物。

管理路線展望

脊髓性肌萎縮症藥物市場按給藥途徑分為口服和注射劑型。 2021年，口服部分在脊髓性肌萎縮症治療市場中佔據了很大的收入份額。 這是由於相關的優勢，例如非侵入性、易於避免疼痛、易消化、適應性和與其他給藥方法相比副作用更少。

區域展望

按地區分析，分析了北美、歐洲、亞太地區和 LAMEA 的脊髓性肌萎縮症治療市場。 北美部分在 2021 年提高了脊髓性肌萎縮症治療市場的最大收入份額。 該地區佔據主導地位的主要驅動因素是 SMA 疾病發病率的增加和治療用品支出的增加。 例如，美國有 10,000 至 25,000 名患有 SMA 的青少年和成年人。

內容

第一章市場範圍與研究方法

  • 市場定義
  • 目的
  • 市場規模
  • 細分
    • 全球脊髓性肌萎縮症治療市場，按類型
    • 全球脊髓性肌萎縮症治療市場，按給藥途徑
    • 全球脊髓性肌萎縮症治療市場，按治療類型
    • 全球脊髓性肌萎縮症治療市場，按地區
  • 調查方法

第 2 章市場概述

  • 簡介
    • 概覽
      • 市場構成和情景
  • 影響市場的主要因素
    • 市場驅動因素
    • 市場製約因素

第 3 章脊髓性肌萎縮症治療市場的發展戰略

第 4 章全球脊髓性肌萎縮症治療市場：按類型

  • 第 1 類全球市場：按地區
  • 第 2 類全球市場：按地區
  • 第 3 類全球市場：按地區
  • 第 4 類全球市場：按地區

第 5 章全球脊髓性肌萎縮症治療市場：按給藥途徑

  • 全球注射劑市場：按地區
  • 全球口腔市場：按地區

第 6 章全球脊髓性肌萎縮症治療市場：按治療類型分類

  • 全球藥品市場：按地區
  • 按藥物類型分列的全球脊髓性肌萎縮症治療市場
    • SPINRAZA 全球市場：按地區
    • Zolgensma 的全球市場 (AVXS-101)：按地區
    • 日常全球市場：按地區
    • 世界其他地區的世界市場
  • 全球基因治療市場：按地區

第 7 章：全球脊髓性肌萎縮症治療市場：按地區

  • 北美
    • 按國家/地區劃分的北美脊髓性肌萎縮症治療市場
      • 美國
      • 加拿大
      • 墨西哥
      • 其他北美地區
  • 歐洲
    • 歐洲脊髓性肌萎縮症治療市場：按國家/地區分類
      • 德國
      • 英國
      • 法國
      • 俄羅斯
      • 西班牙
      • 意大利
      • 其他歐洲
  • 亞太地區
    • 亞太地區按國家/地區劃分的脊髓性肌萎縮症治療市場
      • 中國
      • 日本
      • 印度
      • 韓國
      • 新加坡
      • 馬來西亞
      • 其他亞太地區
  • 拉美
    • LAMEA 脊髓性肌萎縮症治療市場：按國家/地區分類
      • 巴西
      • 阿根廷
      • 阿聯酋
      • 沙特阿拉伯
      • 南非
      • 尼日利亞
      • 拉美其他地區

第八章公司簡介

  • PTC Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.（Genentech, Inc.）
  • Biohaven Pharmaceutical Holding Company Ltd.（Pfizer, Inc.）
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • Scholar Rock, Inc.（Scholar Rock Holding Corporation）
  • Cytokinetics, Incorporated
  • Astellas Pharma, Inc.
  • Biogen, Inc.
  • NMD Pharma A/S

The Global Spinal Muscular Atrophy Treatment Market size is expected to reach $11.4 billion by 2028, rising at a market growth of 17.8% CAGR during the forecast period.

An extremely uncommon genetic condition called spinal muscular atrophy (SMA) damages the area of the central nervous system that regulates voluntary muscle movements. SMA is a neurological autosomal recessive genetic condition marked by muscular atrophy and deterioration. It is among the most prevalent genetic diseases with devastating symptoms and the main genetic cause of newborn mortality.

SMA is a genetic condition that runs in families. If the child has SMA, it is likely due to the presence of two faulty genes, one from each parent, in their body. Their system won't be capable of producing a particular form of protein as a result, the cells that govern muscles perish without it. If just one of the parents passes on a defective gene to the child, they will not develop SMA but they will be carriers of the condition.

The child might carry the damaged gene onto their offspring when they are adults. Depending on the type, spinal muscular atrophy symptoms might be very different. The most severe symptoms of Type 1 SMA in children are typically present during the initial six months of their lives and are more severe.

Those with milder kinds may not exhibit symptoms until the children are 18 months or older since they are less severe. Scoliosis, respiratory issues, swallowing and issues in feeding, delayed gross motor abilities, decreased muscle tone and muscle weakness, limited mobility, and delayed tongue motions are all possible signs of SMA.

COVID-19 Impact Analysis

Due to severe lockdown procedures and limited human movement, the COVID-19 pandemic has negatively impacted the spinal muscular atrophy treatment market. Since the majority of funding was used for COVID-19 vaccine production, the money obtained for Research and development activities and medication research for SMA was decreasing. Access to care for people with spinal muscular atrophy (SMA) was adversely affected by the pandemic. For instance, Cure SMA, a non-profit organization, voluntary-driven, dedicated solely to eliminating SMA, launched a poll in an attempt to assess the impact of the pandemic on the SMA community.

Market Growth Factors

Growing R&D Activities For The Spinal Muscular Atrophy Treatment

The prevalence and knowledge of spinal muscular atrophy have significantly increased, which is driving the demand for effective therapy options that improve patient outcomes. There have been two significant product introductions in the field of gene therapy recently. For a very long time, there was no cure for the rare condition spinal muscular atrophy, which frequently resulted in newborns and young children dying.

Increasing Reimbursement Access To Patients

One of the major trends in spinal muscular atrophy (SMA) is expanding the opportunity for the reimbursement of costly medications globally in several countries. This is predicted to have a favorable impact on the uptake of costly gene therapies. France, Germany, Austria, and Italy are a few of the nations that have given all patients access to services that are reimbursed, and Israel and Hong Kong have done the same.

Market Restraining Factors

Extremely High Costs Of The Approved Products

The high cost of treating rare genetic illnesses is one of the main factors that has constrained the expansion of the treatment facility. For instance, Spinraza is expected to cost US$ 708,000 in the first year and US$ 354,000 in each year after that, totaling US$ 3.9 million for the expense of treatment over a ten-year period. While a single Novartis therapy for Zolgensma is expected to cost US$ 2.1 million. By comparison, risdiplam can cost up to $340,000 annually. These expenses can undoubtedly cause serious problems for both patients and their families as well as healthcare professionals.

Type Outlook

Based on type, the spinal muscular atrophy treatment market is categorized into type 1, type 2, type 3, and type 4. The Type 1 segment garnered the highest revenue share in the spinal muscular atrophy treatment market in 2021. The significant prevalence rate is responsible for this growth. About half of all newborn infants with SMA have this kind of SMA, making it more widespread. A number of treatments, notably Zolgensma (onasemnogene abeparvovec-xioi), have received FDA approval for the treatment of type-1 patients.

Treatment Type Outlook

On the basis of treatment type, the spinal muscular atrophy treatment market is divided into gene therapy and drug. The drug segment acquired the largest revenue share in the spinal muscular atrophy treatment market in 2021. The segment is expanding because of the low cost of drug research and development as well as the simplicity of access relative to other treatments. Presently, three major FDA-approved drugs for the treatment of SMA are available on the market.

Route Of Administration Outlook

On the basis of route of administration, the spinal muscular atrophy treatment market is classified into oral and injection. The oral segment recorded a substantial revenue share in the spinal muscular atrophy treatment market in 2021. This is due to benefits like non-invasiveness, simplicity of pain avoidance, digestion, adaptability, and fewer side effects as opposed to other methods of administration methods that are linked with it.

Regional Outlook

Based on region, the spinal muscular atrophy treatment market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the largest revenue share in the spinal muscular atrophy treatment market in 2021. The key drivers of the region's domination are the increasing incidence of SMA conditions and rising spending on treatment supplies. For instance, between 10,000 and 25,000 youngsters and adults reside in the United States who have SMA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Strategies Deployed in Spinal Muscular Atrophy Market

May-2022: Genentech received approval from FDA for Evrysdi (risdiplam) for use in babies under two months with SMA. Evrysdi (risdiplam) is an early treatment for SMA and can be taken at home.

Feb-2022: Biohaven signed an agreement with Bristol Myers Squibb, a US-based pharmaceutical company primarily into developing, and discovering therapeutics. The agreement involves transferring the development and commercialization rights of taldefgrobep alfa, a phase-3 ready anti-myostatin adnectin. This transfer of rights broadened Biohaven's product portfolio of psychiatric, neuroinflammatory, and neurologic treatments.

Mar-2021: PTC Therapeutics got approval from European Commission for Evrysdi, a liquid dose, developed to treat Spinal Muscular Atrophy, which can be taken at home, and can be taken by both children and adults.

Mar-2021: PTC extended its partnership with Spinal Muscular Atrophy (SMA) Foundation, a non-profit organization focused on developing treatments for SMA. The expansion aims to reinforce drug discovery and development research focused on regenerative medicine.

Oct-2020: Ionis completed the acquisition of Akcea Therapeutics, a biopharmaceutical firm engaged in developing and marketing therapies and medicines focused on treating patients with rare diseases. This acquisition enables Ionis to generate value from Akcea's underway therapies and products.

Jun-2020: PTC took over Censa Pharmaceuticals, a biopharmaceutical company primarily into developing CNSA-001 (sepiapterin), a pharmacological treatment meant for orphan metabolic diseases. This acquisition reinforced PTC's existing rare disease portfolio.

May-2020: NMD Pharma expanded its geographical footprint by establishing a new subsidiary, NMD Pharma US, Inc. in the United States. This expansion aligns with NMD's growth strategy and enables them to further reinforce and expand their pipeline in rare neuromuscular diseases.

Mar-2020: Novartis received approval for Zolgensma from the Japanese Ministry of Health, Labour, and Welfare. Zolgensma is a gene therapy for patients below the age of two years suffering from spinal muscular atrophy. A single dose of Zolgensma is capable of making a significant positive impact on the patient's condition.

Nov-2018: Genentech acquired Jecure Therapeutics, a biotech company focused on developing drugs for inflammatory diseases. The acquisition complemented Genentech's proficiency in NLRP3 biology and enabled them to better take care of patients with inflammatory diseases.

Aug-2018: PTC acquired Agilis Biotherapeutics, a biotechnology company primarily developing DNA therapeutics focused on rare diseases. This acquisition lines up with PTC's aim of being a leader in rare disorders treatment.

May-2018: Novartis acquired AveXis, a biotechnology company providing treatment services for rare neurological genetic disorders. This acquisition aligns with Novartis's plan to provide life-changing innovation for unmet medical requirements and further complements its expanding pipeline of gene therapies focused on the treatment of diseases ranging from SMA to blindness.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Type 1
  • Type 2
  • Type 3
  • Type 4

By Route of Administration

  • Injection
  • Oral

By Treatment Type

  • Drug
    • Spinraza
    • Zolgensma (AVXS-101)
    • Evrysdi
    • Others
  • Gene Therapy

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled:

  • Biogen, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • PTC Therapeutics, Inc.
  • NMD Pharma A/S
  • Scholar Rock, Inc. (Scholar Rock Holding Corporation)
  • Cytokinetics, Inc.
  • Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
  • Astellas Pharma, Inc.
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Spinal Muscular Atrophy Market, by Type
    • 1.4.2 Global Spinal Muscular Atrophy Market, by Route of Administration
    • 1.4.3 Global Spinal Muscular Atrophy Market, by Treatment Type
    • 1.4.4 Global Spinal Muscular Atrophy Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Strategies Deployed in Spinal Muscular Atrophy Market

Chapter 4. Global Spinal Muscular Atrophy Treatment Market by Type

  • 4.1 Global Type 1 Market by Region
  • 4.2 Global Type 2 Market by Region
  • 4.3 Global Type 3 Market by Region
  • 4.4 Global Type 4 Market by Region

Chapter 5. Global Spinal Muscular Atrophy Treatment Market by Route of Administration

  • 5.1 Global Injection Market by Region
  • 5.2 Global Oral Market by Region

Chapter 6. Global Spinal Muscular Atrophy Treatment Market by Treatment Type

  • 6.1 Global Drug Market by Region
  • 6.2 Global Spinal Muscular Atrophy Treatment Market by Drug Type
    • 6.2.1 Global Spinraza Market by Region
    • 6.2.2 Global Zolgensma (AVXS-101) Market by Region
    • 6.2.3 Global Evrysdi Market by Region
    • 6.2.4 Global Others Market by Region
  • 6.3 Global Gene Therapy Market by Region

Chapter 7. Global Spinal Muscular Atrophy Treatment Market by Region

  • 7.1 North America Spinal Muscular Atrophy Treatment Market
    • 7.1.1 North America Spinal Muscular Atrophy Treatment Market by Type
      • 7.1.1.1 North America Type 1 Market by Country
      • 7.1.1.2 North America Type 2 Market by Country
      • 7.1.1.3 North America Type 3 Market by Country
      • 7.1.1.4 North America Type 4 Market by Country
    • 7.1.2 North America Spinal Muscular Atrophy Treatment Market by Route of Administration
      • 7.1.2.1 North America Injection Market by Country
      • 7.1.2.2 North America Oral Market by Country
    • 7.1.3 North America Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.1.3.1 North America Drug Market by Country
      • 7.1.3.2 North America Spinal Muscular Atrophy Treatment Market by Drug Type
        • 7.1.3.2.1 North America Spinraza Market by Country
        • 7.1.3.2.2 North America Zolgensma (AVXS-101) Market by Country
        • 7.1.3.2.3 North America Evrysdi Market by Country
        • 7.1.3.2.4 North America Others Market by Country
      • 7.1.3.3 North America Gene Therapy Market by Country
    • 7.1.4 North America Spinal Muscular Atrophy Treatment Market by Country
      • 7.1.4.1 US Spinal Muscular Atrophy Treatment Market
        • 7.1.4.1.1 US Spinal Muscular Atrophy Treatment Market by Type
        • 7.1.4.1.2 US Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.1.4.1.3 US Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.1.4.1.3.1 US Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.1.4.2 Canada Spinal Muscular Atrophy Treatment Market
        • 7.1.4.2.1 Canada Spinal Muscular Atrophy Treatment Market by Type
        • 7.1.4.2.2 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.1.4.2.3 Canada Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.1.4.2.3.1 Canada Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.1.4.3 Mexico Spinal Muscular Atrophy Treatment Market
        • 7.1.4.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Type
        • 7.1.4.3.2 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.1.4.3.3 Mexico Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.1.4.3.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.1.4.4 Rest of North America Spinal Muscular Atrophy Treatment Market
        • 7.1.4.4.1 Rest of North America Spinal Muscular Atrophy Treatment Market by Type
        • 7.1.4.4.2 Rest of North America Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.1.4.4.3 Rest of North America Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.1.4.4.3.1 Rest of North America Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.2 Europe Spinal Muscular Atrophy Treatment Market
    • 7.2.1 Europe Spinal Muscular Atrophy Treatment Market by Type
      • 7.2.1.1 Europe Type 1 Market by Country
      • 7.2.1.2 Europe Type 2 Market by Country
      • 7.2.1.3 Europe Type 3 Market by Country
      • 7.2.1.4 Europe Type 4 Market by Country
    • 7.2.2 Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
      • 7.2.2.1 Europe Injection Market by Country
      • 7.2.2.2 Europe Oral Market by Country
    • 7.2.3 Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.2.3.1 Europe Drug Market by Country
      • 7.2.3.2 Europe Spinal Muscular Atrophy Treatment Market by Drug Type
        • 7.2.3.2.1 Europe Spinraza Market by Country
        • 7.2.3.2.2 Europe Zolgensma (AVXS-101) Market by Country
        • 7.2.3.2.3 Europe Evrysdi Market by Country
        • 7.2.3.2.4 Europe Others Market by Country
      • 7.2.3.3 Europe Gene Therapy Market by Country
    • 7.2.4 Europe Spinal Muscular Atrophy Treatment Market by Country
      • 7.2.4.1 Germany Spinal Muscular Atrophy Treatment Market
        • 7.2.4.1.1 Germany Spinal Muscular Atrophy Treatment Market by Type
        • 7.2.4.1.2 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.2.4.1.3 Germany Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.2.4.1.3.1 Germany Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.2.4.2 UK Spinal Muscular Atrophy Treatment Market
        • 7.2.4.2.1 UK Spinal Muscular Atrophy Treatment Market by Type
        • 7.2.4.2.2 UK Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.2.4.2.3 UK Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.2.4.2.3.1 UK Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.2.4.3 France Spinal Muscular Atrophy Treatment Market
        • 7.2.4.3.1 France Spinal Muscular Atrophy Treatment Market by Type
        • 7.2.4.3.2 France Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.2.4.3.3 France Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.2.4.3.3.1 France Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.2.4.4 Russia Spinal Muscular Atrophy Treatment Market
        • 7.2.4.4.1 Russia Spinal Muscular Atrophy Treatment Market by Type
        • 7.2.4.4.2 Russia Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.2.4.4.3 Russia Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.2.4.4.3.1 Russia Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.2.4.5 Spain Spinal Muscular Atrophy Treatment Market
        • 7.2.4.5.1 Spain Spinal Muscular Atrophy Treatment Market by Type
        • 7.2.4.5.2 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.2.4.5.3 Spain Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.2.4.5.3.1 Spain Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.2.4.6 Italy Spinal Muscular Atrophy Treatment Market
        • 7.2.4.6.1 Italy Spinal Muscular Atrophy Treatment Market by Type
        • 7.2.4.6.2 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.2.4.6.3 Italy Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.2.4.6.3.1 Italy Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.2.4.7 Rest of Europe Spinal Muscular Atrophy Treatment Market
        • 7.2.4.7.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Type
        • 7.2.4.7.2 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.2.4.7.3 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.2.4.7.3.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.3 Asia Pacific Spinal Muscular Atrophy Treatment Market
    • 7.3.1 Asia Pacific Spinal Muscular Atrophy Treatment Market by Type
      • 7.3.1.1 Asia Pacific Type 1 Market by Country
      • 7.3.1.2 Asia Pacific Type 2 Market by Country
      • 7.3.1.3 Asia Pacific Type 3 Market by Country
      • 7.3.1.4 Asia Pacific Type 4 Market by Country
    • 7.3.2 Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
      • 7.3.2.1 Asia Pacific Injection Market by Country
      • 7.3.2.2 Asia Pacific Oral Market by Country
    • 7.3.3 Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.3.3.1 Asia Pacific Drug Market by Country
      • 7.3.3.2 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type
        • 7.3.3.2.1 Asia Pacific Spinraza Market by Country
        • 7.3.3.2.2 Asia Pacific Zolgensma (AVXS-101) Market by Country
        • 7.3.3.2.3 Asia Pacific Evrysdi Market by Country
        • 7.3.3.2.4 Asia Pacific Others Market by Country
      • 7.3.3.3 Asia Pacific Gene Therapy Market by Country
    • 7.3.4 Asia Pacific Spinal Muscular Atrophy Treatment Market by Country
      • 7.3.4.1 China Spinal Muscular Atrophy Treatment Market
        • 7.3.4.1.1 China Spinal Muscular Atrophy Treatment Market by Type
        • 7.3.4.1.2 China Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.3.4.1.3 China Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.3.4.1.3.1 China Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.3.4.2 Japan Spinal Muscular Atrophy Treatment Market
        • 7.3.4.2.1 Japan Spinal Muscular Atrophy Treatment Market by Type
        • 7.3.4.2.2 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.3.4.2.3 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.3.4.2.3.1 Japan Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.3.4.3 India Spinal Muscular Atrophy Treatment Market
        • 7.3.4.3.1 India Spinal Muscular Atrophy Treatment Market by Type
        • 7.3.4.3.2 India Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.3.4.3.3 India Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.3.4.3.3.1 India Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.3.4.4 South Korea Spinal Muscular Atrophy Treatment Market
        • 7.3.4.4.1 South Korea Spinal Muscular Atrophy Treatment Market by Type
        • 7.3.4.4.2 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.3.4.4.3 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.3.4.4.3.1 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.3.4.5 Australia Spinal Muscular Atrophy Treatment Market
        • 7.3.4.5.1 Australia Spinal Muscular Atrophy Treatment Market by Type
        • 7.3.4.5.2 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.3.4.5.3 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.3.4.5.3.1 Australia Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.3.4.6 Malaysia Spinal Muscular Atrophy Treatment Market
        • 7.3.4.6.1 Malaysia Spinal Muscular Atrophy Treatment Market by Type
        • 7.3.4.6.2 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.3.4.6.3 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.3.4.6.3.1 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.3.4.7 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market
        • 7.3.4.7.1 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type
        • 7.3.4.7.2 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.3.4.7.3 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.3.4.7.3.1 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.4 LAMEA Spinal Muscular Atrophy Treatment Market
    • 7.4.1 LAMEA Spinal Muscular Atrophy Treatment Market by Type
      • 7.4.1.1 LAMEA Type 1 Market by Country
      • 7.4.1.2 LAMEA Type 2 Market by Country
      • 7.4.1.3 LAMEA Type 3 Market by Country
      • 7.4.1.4 LAMEA Type 4 Market by Country
    • 7.4.2 LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration
      • 7.4.2.1 LAMEA Injection Market by Country
      • 7.4.2.2 LAMEA Oral Market by Country
    • 7.4.3 LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.4.3.1 LAMEA Drug Market by Country
      • 7.4.3.2 LAMEA Spinal Muscular Atrophy Treatment Market by Drug Type
        • 7.4.3.2.1 LAMEA Spinraza Market by Country
        • 7.4.3.2.2 LAMEA Zolgensma (AVXS-101) Market by Country
        • 7.4.3.2.3 LAMEA Evrysdi Market by Country
        • 7.4.3.2.4 LAMEA Others Market by Country
      • 7.4.3.3 LAMEA Gene Therapy Market by Country
    • 7.4.4 LAMEA Spinal Muscular Atrophy Treatment Market by Country
      • 7.4.4.1 Brazil Spinal Muscular Atrophy Treatment Market
        • 7.4.4.1.1 Brazil Spinal Muscular Atrophy Treatment Market by Type
        • 7.4.4.1.2 Brazil Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.4.4.1.3 Brazil Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.4.4.1.3.1 Brazil Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.4.4.2 Argentina Spinal Muscular Atrophy Treatment Market
        • 7.4.4.2.1 Argentina Spinal Muscular Atrophy Treatment Market by Type
        • 7.4.4.2.2 Argentina Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.4.4.2.3 Argentina Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.4.4.2.3.1 Argentina Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.4.4.3 UAE Spinal Muscular Atrophy Treatment Market
        • 7.4.4.3.1 UAE Spinal Muscular Atrophy Treatment Market by Type
        • 7.4.4.3.2 UAE Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.4.4.3.3 UAE Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.4.4.3.3.1 UAE Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.4.4.4 Saudi Arabia Spinal Muscular Atrophy Treatment Market
        • 7.4.4.4.1 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Type
        • 7.4.4.4.2 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.4.4.4.3 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.4.4.4.3.1 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.4.4.5 South Africa Spinal Muscular Atrophy Treatment Market
        • 7.4.4.5.1 South Africa Spinal Muscular Atrophy Treatment Market by Type
        • 7.4.4.5.2 South Africa Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.4.4.5.3 South Africa Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.4.4.5.3.1 South Africa Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.4.4.6 Nigeria Spinal Muscular Atrophy Treatment Market
        • 7.4.4.6.1 Nigeria Spinal Muscular Atrophy Treatment Market by Type
        • 7.4.4.6.2 Nigeria Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.4.4.6.3 Nigeria Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.4.4.6.3.1 Nigeria Spinal Muscular Atrophy Treatment Market by Drug Type
      • 7.4.4.7 Rest of LAMEA Spinal Muscular Atrophy Treatment Market
        • 7.4.4.7.1 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Type
        • 7.4.4.7.2 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration
        • 7.4.4.7.3 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type
          • 7.4.4.7.3.1 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Drug Type

Chapter 8. Company Profiles

  • 8.1 PTC Therapeutics, Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Regional Analysis
    • 8.1.4 Research & Development Expenses
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Partnerships, Collaborations, and Agreements:
      • 8.1.5.2 Acquisition and Mergers:
      • 8.1.5.3 Approvals and Trials:
  • 8.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Segmental and Regional Analysis
    • 8.2.4 Research & Development Expense
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Approvals and Trials:
      • 8.2.5.2 Acquisition and Mergers:
  • 8.3 Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Regional & Segmental Analysis
    • 8.3.4 Research & Development Expense
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Partnerships, Collaborations, and Agreements:
  • 8.4 Novartis AG
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Research & Development Expense
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Approvals and Trials:
      • 8.4.5.2 Acquisition and Mergers:
  • 8.5 Ionis Pharmaceuticals, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Research & Development Expenses
    • 8.5.4 Recent strategies and developments:
      • 8.5.4.1 Acquisition and Mergers:
  • 8.6 Scholar Rock, Inc. (Scholar Rock Holding Corporation)
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Research & Development Expenses
  • 8.7 Cytokinetics, Incorporated
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Research & Development Expenses
  • 8.8 Astellas Pharma, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Regional Analysis
    • 8.8.4 Research & Development Expense
  • 8.9 Biogen, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional Analysis
    • 8.9.4 Research & Development Expense
  • 8.10. NMD Pharma A/S
    • 8.10.1 Company Overview
    • 8.10.2 Recent strategies and developments:
      • 8.10.2.1 Geographical Expansions:

LIST OF TABLES

  • TABLE 1 Global Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 2 Global Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 3 Global Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 4 Global Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 5 Global Type 1 Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Type 1 Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Type 2 Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Type 2 Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global Type 3 Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global Type 3 Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Type 4 Market by Region, 2018 - 2021, USD Million
  • TABLE 12 Global Type 4 Market by Region, 2022 - 2028, USD Million
  • TABLE 13 Global Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 14 Global Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 15 Global Injection Market by Region, 2018 - 2021, USD Million
  • TABLE 16 Global Injection Market by Region, 2022 - 2028, USD Million
  • TABLE 17 Global Oral Market by Region, 2018 - 2021, USD Million
  • TABLE 18 Global Oral Market by Region, 2022 - 2028, USD Million
  • TABLE 19 Global Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 20 Global Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 21 Global Drug Market by Region, 2018 - 2021, USD Million
  • TABLE 22 Global Drug Market by Region, 2022 - 2028, USD Million
  • TABLE 23 Global Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 24 Global Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 25 Global Spinraza Market by Region, 2018 - 2021, USD Million
  • TABLE 26 Global Spinraza Market by Region, 2022 - 2028, USD Million
  • TABLE 27 Global Zolgensma (AVXS-101) Market by Region, 2018 - 2021, USD Million
  • TABLE 28 Global Zolgensma (AVXS-101) Market by Region, 2022 - 2028, USD Million
  • TABLE 29 Global Evrysdi Market by Region, 2018 - 2021, USD Million
  • TABLE 30 Global Evrysdi Market by Region, 2022 - 2028, USD Million
  • TABLE 31 Global Others Market by Region, 2018 - 2021, USD Million
  • TABLE 32 Global Others Market by Region, 2022 - 2028, USD Million
  • TABLE 33 Global Gene Therapy Market by Region, 2018 - 2021, USD Million
  • TABLE 34 Global Gene Therapy Market by Region, 2022 - 2028, USD Million
  • TABLE 35 Global Spinal Muscular Atrophy Treatment Market by Region, 2018 - 2021, USD Million
  • TABLE 36 Global Spinal Muscular Atrophy Treatment Market by Region, 2022 - 2028, USD Million
  • TABLE 37 North America Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 38 North America Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 39 North America Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 40 North America Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 41 North America Type 1 Market by Country, 2018 - 2021, USD Million
  • TABLE 42 North America Type 1 Market by Country, 2022 - 2028, USD Million
  • TABLE 43 North America Type 2 Market by Country, 2018 - 2021, USD Million
  • TABLE 44 North America Type 2 Market by Country, 2022 - 2028, USD Million
  • TABLE 45 North America Type 3 Market by Country, 2018 - 2021, USD Million
  • TABLE 46 North America Type 3 Market by Country, 2022 - 2028, USD Million
  • TABLE 47 North America Type 4 Market by Country, 2018 - 2021, USD Million
  • TABLE 48 North America Type 4 Market by Country, 2022 - 2028, USD Million
  • TABLE 49 North America Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 50 North America Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 51 North America Injection Market by Country, 2018 - 2021, USD Million
  • TABLE 52 North America Injection Market by Country, 2022 - 2028, USD Million
  • TABLE 53 North America Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 54 North America Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 55 North America Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 56 North America Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 57 North America Drug Market by Country, 2018 - 2021, USD Million
  • TABLE 58 North America Drug Market by Country, 2022 - 2028, USD Million
  • TABLE 59 North America Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 60 North America Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 61 North America Spinraza Market by Country, 2018 - 2021, USD Million
  • TABLE 62 North America Spinraza Market by Country, 2022 - 2028, USD Million
  • TABLE 63 North America Zolgensma (AVXS-101) Market by Country, 2018 - 2021, USD Million
  • TABLE 64 North America Zolgensma (AVXS-101) Market by Country, 2022 - 2028, USD Million
  • TABLE 65 North America Evrysdi Market by Country, 2018 - 2021, USD Million
  • TABLE 66 North America Evrysdi Market by Country, 2022 - 2028, USD Million
  • TABLE 67 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 68 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 69 North America Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 70 North America Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 71 North America Spinal Muscular Atrophy Treatment Market by Country, 2018 - 2021, USD Million
  • TABLE 72 North America Spinal Muscular Atrophy Treatment Market by Country, 2022 - 2028, USD Million
  • TABLE 73 US Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 74 US Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 75 US Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 76 US Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 77 US Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 78 US Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 79 US Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 80 US Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 81 US Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 82 US Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 83 Canada Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 84 Canada Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 85 Canada Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 86 Canada Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 87 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 88 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 89 Canada Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 90 Canada Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 91 Canada Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 92 Canada Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 93 Mexico Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 94 Mexico Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 95 Mexico Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 96 Mexico Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 97 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 98 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 99 Mexico Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 100 Mexico Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 101 Mexico Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 102 Mexico Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 103 Rest of North America Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 104 Rest of North America Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 105 Rest of North America Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 106 Rest of North America Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 107 Rest of North America Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 108 Rest of North America Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 109 Rest of North America Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 110 Rest of North America Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 111 Rest of North America Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 112 Rest of North America Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 113 Europe Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 114 Europe Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 115 Europe Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 116 Europe Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 117 Europe Type 1 Market by Country, 2018 - 2021, USD Million
  • TABLE 118 Europe Type 1 Market by Country, 2022 - 2028, USD Million
  • TABLE 119 Europe Type 2 Market by Country, 2018 - 2021, USD Million
  • TABLE 120 Europe Type 2 Market by Country, 2022 - 2028, USD Million
  • TABLE 121 Europe Type 3 Market by Country, 2018 - 2021, USD Million
  • TABLE 122 Europe Type 3 Market by Country, 2022 - 2028, USD Million
  • TABLE 123 Europe Type 4 Market by Country, 2018 - 2021, USD Million
  • TABLE 124 Europe Type 4 Market by Country, 2022 - 2028, USD Million
  • TABLE 125 Europe Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 126 Europe Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 127 Europe Injection Market by Country, 2018 - 2021, USD Million
  • TABLE 128 Europe Injection Market by Country, 2022 - 2028, USD Million
  • TABLE 129 Europe Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 130 Europe Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 131 Europe Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 132 Europe Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 133 Europe Drug Market by Country, 2018 - 2021, USD Million
  • TABLE 134 Europe Drug Market by Country, 2022 - 2028, USD Million
  • TABLE 135 Europe Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 136 Europe Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 137 Europe Spinraza Market by Country, 2018 - 2021, USD Million
  • TABLE 138 Europe Spinraza Market by Country, 2022 - 2028, USD Million
  • TABLE 139 Europe Zolgensma (AVXS-101) Market by Country, 2018 - 2021, USD Million
  • TABLE 140 Europe Zolgensma (AVXS-101) Market by Country, 2022 - 2028, USD Million
  • TABLE 141 Europe Evrysdi Market by Country, 2018 - 2021, USD Million
  • TABLE 142 Europe Evrysdi Market by Country, 2022 - 2028, USD Million
  • TABLE 143 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 144 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 145 Europe Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 146 Europe Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 147 Europe Spinal Muscular Atrophy Treatment Market by Country, 2018 - 2021, USD Million
  • TABLE 148 Europe Spinal Muscular Atrophy Treatment Market by Country, 2022 - 2028, USD Million
  • TABLE 149 Germany Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 150 Germany Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 151 Germany Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 152 Germany Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 153 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 154 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 155 Germany Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 156 Germany Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 157 Germany Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 158 Germany Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 159 UK Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 160 UK Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 161 UK Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 162 UK Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 163 UK Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 164 UK Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 165 UK Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 166 UK Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 167 UK Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 168 UK Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 169 France Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 170 France Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 171 France Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 172 France Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 173 France Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 174 France Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 175 France Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 176 France Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 177 France Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 178 France Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 179 Russia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 180 Russia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 181 Russia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 182 Russia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 183 Russia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 184 Russia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 185 Russia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 186 Russia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 187 Russia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 188 Russia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 189 Spain Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 190 Spain Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 191 Spain Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 192 Spain Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 193 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 194 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 195 Spain Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 196 Spain Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 197 Spain Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 198 Spain Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 199 Italy Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 200 Italy Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 201 Italy Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 202 Italy Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 203 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 204 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 205 Italy Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 206 Italy Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 207 Italy Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 208 Italy Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 209 Rest of Europe Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 210 Rest of Europe Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 211 Rest of Europe Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 212 Rest of Europe Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 213 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 214 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 215 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 216 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 217 Rest of Europe Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 218 Rest of Europe Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 219 Asia Pacific Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 220 Asia Pacific Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 221 Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 222 Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 223 Asia Pacific Type 1 Market by Country, 2018 - 2021, USD Million
  • TABLE 224 Asia Pacific Type 1 Market by Country, 2022 - 2028, USD Million
  • TABLE 225 Asia Pacific Type 2 Market by Country, 2018 - 2021, USD Million
  • TABLE 226 Asia Pacific Type 2 Market by Country, 2022 - 2028, USD Million
  • TABLE 227 Asia Pacific Type 3 Market by Country, 2018 - 2021, USD Million
  • TABLE 228 Asia Pacific Type 3 Market by Country, 2022 - 2028, USD Million
  • TABLE 229 Asia Pacific Type 4 Market by Country, 2018 - 2021, USD Million
  • TABLE 230 Asia Pacific Type 4 Market by Country, 2022 - 2028, USD Million
  • TABLE 231 Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 232 Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 233 Asia Pacific Injection Market by Country, 2018 - 2021, USD Million
  • TABLE 234 Asia Pacific Injection Market by Country, 2022 - 2028, USD Million
  • TABLE 235 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 236 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 237 Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 238 Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 239 Asia Pacific Drug Market by Country, 2018 - 2021, USD Million
  • TABLE 240 Asia Pacific Drug Market by Country, 2022 - 2028, USD Million
  • TABLE 241 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 242 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 243 Asia Pacific Spinraza Market by Country, 2018 - 2021, USD Million
  • TABLE 244 Asia Pacific Spinraza Market by Country, 2022 - 2028, USD Million
  • TABLE 245 Asia Pacific Zolgensma (AVXS-101) Market by Country, 2018 - 2021, USD Million
  • TABLE 246 Asia Pacific Zolgensma (AVXS-101) Market by Country, 2022 - 2028, USD Million
  • TABLE 247 Asia Pacific Evrysdi Market by Country, 2018 - 2021, USD Million
  • TABLE 248 Asia Pacific Evrysdi Market by Country, 2022 - 2028, USD Million
  • TABLE 249 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 250 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 251 Asia Pacific Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 252 Asia Pacific Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 253 Asia Pacific Spinal Muscular Atrophy Treatment Market by Country, 2018 - 2021, USD Million
  • TABLE 254 Asia Pacific Spinal Muscular Atrophy Treatment Market by Country, 2022 - 2028, USD Million
  • TABLE 255 China Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 256 China Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 257 China Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 258 China Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 259 China Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 260 China Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 261 China Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 262 China Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 263 China Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 264 China Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 265 Japan Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 266 Japan Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 267 Japan Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 268 Japan Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 269 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 270 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 271 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 272 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 273 Japan Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 274 Japan Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 275 India Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 276 India Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 277 India Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 278 India Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 279 India Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 280 India Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 281 India Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 282 India Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 283 India Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 284 India Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 285 South Korea Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 286 South Korea Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 287 South Korea Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 288 South Korea Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 289 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 290 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 291 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 292 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 293 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 294 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 295 Australia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 296 Australia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 297 Australia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 298 Australia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 299 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 300 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 301 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 302 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 303 Australia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 304 Australia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 305 Malaysia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 306 Malaysia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 307 Malaysia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 308 Malaysia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 309 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 310 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 311 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 312 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 313 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 314 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 315 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 316 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 317 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 318 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 319 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 320 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 321 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 322 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 323 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 324 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 325 LAMEA Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 326 LAMEA Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 327 LAMEA Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 328 LAMEA Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 329 LAMEA Type 1 Market by Country, 2018 - 2021, USD Million
  • TABLE 330 LAMEA Type 1 Market by Country, 2022 - 2028, USD Million
  • TABLE 331 LAMEA Type 2 Market by Country, 2018 - 2021, USD Million
  • TABLE 332 LAMEA Type 2 Market by Country, 2022 - 2028, USD Million
  • TABLE 333 LAMEA Type 3 Market by Country, 2018 - 2021, USD Million
  • TABLE 334 LAMEA Type 3 Market by Country, 2022 - 2028, USD Million
  • TABLE 335 LAMEA Type 4 Market by Country, 2018 - 2021, USD Million
  • TABLE 336 LAMEA Type 4 Market by Country, 2022 - 2028, USD Million
  • TABLE 337 LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 338 LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 339 LAMEA Injection Market by Country, 2018 - 2021, USD Million
  • TABLE 340 LAMEA Injection Market by Country, 2022 - 2028, USD Million
  • TABLE 341 LAMEA Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 342 LAMEA Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 343 LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 344 LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 345 LAMEA Drug Market by Country, 2018 - 2021, USD Million
  • TABLE 346 LAMEA Drug Market by Country, 2022 - 2028, USD Million
  • TABLE 347 LAMEA Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 348 LAMEA Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 349 LAMEA Spinraza Market by Country, 2018 - 2021, USD Million
  • TABLE 350 LAMEA Spinraza Market by Country, 2022 - 2028, USD Million
  • TABLE 351 LAMEA Zolgensma (AVXS-101) Market by Country, 2018 - 2021, USD Million
  • TABLE 352 LAMEA Zolgensma (AVXS-101) Market by Country, 2022 - 2028, USD Million
  • TABLE 353 LAMEA Evrysdi Market by Country, 2018 - 2021, USD Million
  • TABLE 354 LAMEA Evrysdi Market by Country, 2022 - 2028, USD Million
  • TABLE 355 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 356 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 357 LAMEA Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 358 LAMEA Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 359 LAMEA Spinal Muscular Atrophy Treatment Market by Country, 2018 - 2021, USD Million
  • TABLE 360 LAMEA Spinal Muscular Atrophy Treatment Market by Country, 2022 - 2028, USD Million
  • TABLE 361 Brazil Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 362 Brazil Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 363 Brazil Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 364 Brazil Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 365 Brazil Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 366 Brazil Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 367 Brazil Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 368 Brazil Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 369 Brazil Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 370 Brazil Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 371 Argentina Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 372 Argentina Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 373 Argentina Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 374 Argentina Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 375 Argentina Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 376 Argentina Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 377 Argentina Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 378 Argentina Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 379 Argentina Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 380 Argentina Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 381 UAE Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 382 UAE Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 383 UAE Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 384 UAE Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 385 UAE Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 386 UAE Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 387 UAE Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 388 UAE Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 389 UAE Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 390 UAE Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 391 Saudi Arabia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 392 Saudi Arabia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 393 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 394 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 395 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 396 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 397 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 398 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 399 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 400 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 401 South Africa Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 402 South Africa Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 403 South Africa Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 404 South Africa Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 405 South Africa Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 406 South Africa Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 407 South Africa Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 408 South Africa Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 409 South Africa Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 410 South Africa Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 411 Nigeria Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 412 Nigeria Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 413 Nigeria Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 414 Nigeria Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 415 Nigeria Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 416 Nigeria Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 417 Nigeria Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 418 Nigeria Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 419 Nigeria Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 420 Nigeria Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 421 Rest of LAMEA Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 422 Rest of LAMEA Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 423 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 424 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 425 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 426 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 427 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 428 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 429 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 430 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 431 Key Information - PTC Therapeutics, Inc.
  • TABLE 432 key information - F. Hoffmann-La Roche Ltd.
  • TABLE 433 Key Information - Biohaven Pharmaceutical Holding Company Ltd.
  • TABLE 434 Key Information - Novartis AG
  • TABLE 435 Key information - Ionis Pharmaceuticals, Inc.
  • TABLE 436 Key Information - Scholar Rock, Inc.
  • TABLE 437 Key Information - CYTOKINETICS, INCORPORATED
  • TABLE 438 key information - Astellas Pharma, Inc.
  • TABLE 439 Key Information - Biogen, Inc.
  • TABLE 440 Key Information - nmd pharma a/s

LIST OF FIGURES

  • FIG 1 Methodology for the research
  • FIG 2 Global Spinal Muscular Atrophy Treatment Market Share by Type, 2021
  • FIG 3 Global Spinal Muscular Atrophy Treatment Market Share by Type, 2028
  • FIG 4 Global Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2028, USD Million
  • FIG 5 Global Spinal Muscular Atrophy Treatment Market Share by Route of Administration, 2021
  • FIG 6 Global Spinal Muscular Atrophy Treatment Market Share by Route of Administration, 2028
  • FIG 7 Global Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2028, USD Million
  • FIG 8 Global Spinal Muscular Atrophy Treatment Market Share by Treatment Type, 2021
  • FIG 9 Global Spinal Muscular Atrophy Treatment Market Share by Treatment Type, 2028
  • FIG 10 Global Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2028, USD Million
  • FIG 11 Global Spinal Muscular Atrophy Treatment Market Share by Region, 2021
  • FIG 12 Global Spinal Muscular Atrophy Treatment Market Share by Region, 2028
  • FIG 13 Global Spinal Muscular Atrophy Treatment Market by Region, 2018 - 2028, USD Million
  • FIG 14 Recent strategies and developments: PTC Therapeutics, Inc.